Vitasora Health Allocates 800,000 Shares at $0.01 Each to Settle Broker Fees After Capital Raise

Vitasora Health Issues 800,000 Broker Fee Shares at $0.01 Post Capital Raise

Vitasora Health Limited has formally applied to the ASX to quote 800,000 fully paid ordinary shares issued as broker fees related to a recent capital raise. These shares were allotted on 2 July 2026 at $0.01 each, representing a 4% fee calculated on the gross funds received. The company lodged the Appendix 2A quotation application on 3 July 2026.

Issuing shares instead of cash to cover broker fees is a common practice in Australian small-cap markets, aligning broker interests with the company’s by providing equity exposure while conserving cash. The company did not disclose the total gross amount raised in the capital raise within this update, so the exact monetary value of the broker fee cannot be independently determined from the information provided.

Application of the 4% Broker Fee to the Capital Raise

The update confirms the 800,000 shares were issued as payment for broker services related to the capital raise. The fee was set at 4% of the gross funds raised and paid in ordinary shares priced at $0.01 each instead of cash. This share-based fee complies with ASX Listing Rules and does not require a separate prospectus or product disclosure statement, assuming compliance with Corporations Act on-sale provisions.

Vitasora Health stated that any resale of these shares within 12 months of issuance will comply with sections 707(3) and 1012C(6) of the Corporations Act through the publication of a cleansing notice. This is standard practice, and the company confirmed the cleansing notice requirement was addressed as part of the quotation application.

Total Shares Reach 2.34 Billion After Quotation

After listing the 800,000 new shares, Vitasora Health’s total fully paid ordinary shares quoted will be 2,340,427,201. This substantial share count is an important factor for investors in small-cap healthcare stocks to consider when evaluating the company’s capital structure and earnings per share potential.

The share count figures are generated automatically by ASX systems and may not fully reflect the current issued capital if other forms are being processed simultaneously. Vitasora Health noted this standard disclaimer, indicating the final number may vary slightly once all pending filings are completed. The company did not provide additional details on its cash position or specific plans for the capital raised beyond the application.

Shares Issued Under 15% Placement Capacity Without Shareholder Approval

The 800,000 shares were issued using Vitasora Health’s 15% placement capacity under ASX Listing Rule 7.1, which permits companies to issue new securities up to 15% of their share capital without shareholder approval. This mechanism allows companies to quickly raise capital or settle obligations such as broker fees without the delays and costs of convening a meeting.

The company confirmed no shareholder approval was sought or obtained for this issuance and that it did not use the additional 10% capacity available under Listing Rule 7.1A. Utilizing the standard 15% capacity maintains capital management flexibility, though investors should be aware that repeated use of placement capacity can dilute existing shareholders if not offset by growth in company value.

Unquoted Options and Overall Capital Structure

The update also reveals Vitasora Health has a significant number of unquoted options outstanding across multiple tranches, including 35 million options expiring 30 June 2028 at $0.12 per share, another 35 million expiring 30 June 2028 at $0.08, 11 million expiring 8 January 2027 at $0.10, 4 million expiring 8 January 2027 at $0.065, 3.2 million expiring 31 January 2027 at $0.20, and 2 million expiring 9 June 2027 at $0.10.

In total, these options could convert into 90,200,000 additional ordinary shares if exercised. This potential dilution is a material consideration for shareholders, as exercising these options would increase the share count and could impact the market price depending on conditions at exercise. Investors should monitor whether these options are exercised, expire, or are otherwise modified.

Significance of the $0.01 Issue Price

The $0.01 per share price for the broker fee shares is notable, reflecting a capital raise conducted at or near this low level. This price is at the lower end of the ASX pricing spectrum, often associated with penny stock status, and may indicate significant capital restructuring, dilutionary funding rounds, or previous share price declines.

The company did not comment on its current market price or trading conditions related to the capital raise in this update. Investors seeking to understand the context of the $0.01 price should consult publicly available market data. The immediate share price impact of this quotation application is not apparent from public information.

Compliance With Corporations Act On-Sale Restrictions

Vitasora Health confirmed that any resale of the broker fee shares within 12 months of issuance will comply with secondary sale provisions under sections 707(3) and 1012C(6) of the Corporations Act 2001 (Cth) through a cleansing notice. This ensures the broker can sell the shares on the open market without breaching fundraising rules.

Without such a cleansing notice, shares issued without a prospectus or product disclosure statement would generally be restricted from resale for 12 months. By meeting this requirement, the company and broker ensure the shares are fully liquid upon quotation.

Company Background and Strategic Context

Vitasora Health Limited (ASX:VHL), ABN 98 009 234 173, is an ASX-listed healthcare company. This update does not provide operational or financial details beyond the broker fee share issuance and quotation application. Investors seeking broader information should refer to the company’s latest financial statements, investor presentations, and other ASX disclosures.

The issuance of broker fee shares following a capital raise indicates recent market activity to strengthen cash resources. With over 2.34 billion shares outstanding and options potentially adding 90.2 million more, investors and analysts will closely watch how the company deploys the capital and progresses toward strategic goals. The next significant update will likely be operational or financial disclosures contextualizing the recent fundraising.

Investor Considerations After Broker Fee Share Quotation

Post quotation of the 800,000 broker fee shares, investors should monitor disclosures regarding the total capital raised, which was not disclosed in this update. Understanding the raise’s scale will aid assessment of funding for operations and growth.

Additionally, with 90.2 million options outstanding across six tranches—some expiring as early as January 2027—investors will watch for option exercises or lapses. Exercise prices range from $0.065 to $0.20 per share, and exercise likelihood will depend on potential share price appreciation. Investors may also track any changes in management, board composition, or corporate strategy that could influence share price dynamics.